IL-34/TREM2 modulates microglia-mediated inflammation and provides neuroprotection in a mouse model of sporadic Alzheimer's disease
BackgroundAs a recently identified cytokine, interleukin-34 (IL-34) is predominantly produced by neurons and functions as a modulator for glial functions. Emerging evidence indicates that IL-34 exerted neuroprotective effects in Alzheimer's disease (AD), but the underlying mechanism remained elusive.ObjectiveTo uncover the mechanisms by which IL-34 provides neuroprotection in AD.MethodsUsing senescence-accelerated mouse prone substrain 8 (SAMP8) mice, a well-established model for sporadic AD, we investigated the dynamic changes in brain IL-34 concentrations during AD progression. Afterwards, SAMP8 mice received a 4-week continuous intracerebroventricular infusion of IL-34. Morris water maze test was employed to assess the spatial cognitive functions. Neuronal and synaptic markers, oxidative stress makers, pro-inflammatory cytokines and glial activation markers in the brains of SAMP8 mice were measured. Finally, amyloid-β (Aβ)<sub>42</sub>-stimulated primary microglia, lentivirus-mediated gene knockdown strategy and co-immunoprecipitation assay were utilized to uncover the possible mechanisms by which IL-34 exerted neuroprotection in AD.ResultsIn SAMP8 mice, we revealed that brain IL-34 concentrations gradually decreased during AD progression. A 4-week continuous intracerebroventricular infusion of IL-34 rescued spatial cognitive impairments, ameliorated neuronal and synaptic damage, and suppressed oxidative stress and microglia-mediated inflammation in the brains of SAMP8 mice. Using Aβ<sub>42</sub>-stimulated primary microglia, we demonstrated for the first time that IL-34 suppressed microglial NLRP3 inflammasome activation and pro-inflammatory cytokines release by interacting with triggering receptor expressed on myeloid cells 2 (TREM2), a key regulator of microglial functions.ConclusionsThese findings uncover the mechanisms by which IL-34 provides neuroprotection in AD, indicating that IL-34/TREM2 signaling may represent a novel therapeutic strategy for this devastating disease.
Authors
- Jingwen Qi
- Rui Duan (ORCID: https://orcid.org/0000-0001-5035-5633)
- Teng Jiang (ORCID: https://orcid.org/0000-0003-4170-1156)
- Zhi-Hang Huang (ORCID: https://orcid.org/0009-0001-1975-9573)
- Zhihuan Luo (ORCID: https://orcid.org/0000-0002-3616-7115)
- Yingdong Zhang
- Xiaolan Fu
- Shiyao Wang
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Alzheimer s Disease
- Published
- 2025-03-02
- DOI
- https://doi.org/10.1177/13872877251320418
- Citations
- 2
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.68